Evotec SE — Regulatory Filings 2014

May 6, 2014

News Details

Corporate | 6 May 2014 07:29

Evotec and Eternygen enter collaboration to identify and develop novel metabolic disease therapy

DGAP-News: Evotec AG / Key word(s): Alliance

06.05.2014 / 07:29

---

Berlin and Hamburg, Germany - 06 May 2014: Evotec AG (Frankfurt Stock
Exchange: EVT, TecDAX, ISIN: DE0005664809) and Eternygen GmbH, a privately
owned biopharmaceutical company, today announced a drug discovery
collaboration to develop novel small molecule inhibitors against an
Eternygen target to treat metabolic diseases using Evotec's technology
platform and broad expertise in drug discovery and pre-clinical
development. Eternygen is working on the sodium coupled citrate transporter
NaCT, a novel target which is a key regulator of energy metabolism involved
in the pathogenesis of fatty liver, diabetes and obesity.

Under the terms of the agreement, Evotec will use its best-in-class drug
discovery platform to discover and develop a suitable clinical candidate.

Marco Janezic, CEO Eternygen GmbH, said: "Evotec as a world-leading
provider for drug discovery and development services and its deep expertise
in the area of metabolic diseases is the optimal partner for Eternygen as a
project focused company to drive the development process as fast as
possible until proof of concept."

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are
pleased to enter this collaboration with Eternygen and we are confident
that the combination of Eternygen's and our expertise in metabolic drug
discovery and development will lead to success."

ABOUT NACT
NaCT, also known as PMCT or SLC13A5, is a sodium coupled citrate
transporter which is predominantly expressed in liver cells and the
mammalian homolog of the INDY ("I am not dead yet") gene in Drosophila. In
mouse studies it was shown that NaCT knock out protects from adiposity and
insulin resistance induced by aging and high-fat diet. Therefore NaCT is an
attractive therapeutic target for the treatment of non-alcoholic fatty
liver disease, obesity, and type 2 diabetes by influencing the mammalian
energy metabolism.

ABOUT ETERNYGEN GMBH
Eternygen is a Berlin based Biotech Company founded in June 2012 focusing
on research, development and marketing of NaCT inhibitors for the treatment
of dietary-related metabolic diseases. The founding team consists of
renowned scientists from leading German universities as well as serial
entrepreneurs from the venture and industry community. Eternygen is
basically a virtually company using a network of senior industry experts
and contract research organizations to drive the projects forward.
Eternygen is financed by VC Fonds Technologie Berlin managed by IBB
Beteiligungsgesellschaft mbH and two renowned family offices. IBB
Beteiligungsgesellschaft mbH is providing venture capital for Berlin-based
technology-oriented companies. For additional information please go to
www.eternygen.com.

ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca,
Roche and UCB. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim,
MedImmune and Andromeda in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the field of
Alzheimer's disease. For additional information please go to
www.evotec.com.

FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.

Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com

End of Corporate News

---

06.05.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart

End of News DGAP News-Service

266530 06.05.2014